Disaster and Accident Risk Arising from the Concentration of Formulation Production Facilities
First written in FY2018. 3 of 4 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2018: 32 of 131 companies on the "Worse" side.
- FY2025RestatedAnnual report
「Active pharmaceutical ingredient warehouses and quality testing are operated at 2 locations, in Kanagawa and Osaka. However, drug product production is concentrated in Yamagata Prefecture, and not all of our group's facilities can be immediately replaced by alternative facilities. Accordingly, if a disaster or accident occurs, damage to manufacturing equipment and other assets, suspension of production lines, compensation to business partners and nearby residents, and other factors may affect our group's business, operating results and financial condition.」
The disaster and accident risks arising from the dispersed locations of active pharmaceutical ingredient warehouses and quality testing and the concentration of drug product production in Yamagata Prefecture are being reconfirmed. - FY2021RestatedAnnual report
「Because drug product production is concentrated in Yamagata Prefecture and not all of our group's facilities can be immediately replaced by alternative facilities, if a disaster or accident occurs」
The disaster and accident risks associated with the concentration of drug product production in Yamagata Prefecture and the difficulty of securing alternatives are being reconfirmed. - FY2019RestatedAnnual report
「Drug product production is concentrated in Yamagata Prefecture, and not all of our group's facilities can be immediately replaced by alternative facilities. Accordingly, if a disaster or accident occurs, damage to manufacturing equipment and other assets, suspension of production lines, compensation to business partners and nearby residents, and other factors may affect our group's business, operating results and financial condition.」
The disaster and accident risks associated with the concentration of drug product production in Yamagata Prefecture and the difficulty of securing alternatives are being reconfirmed. - FY2018First statedAnnual report
「Drug product production is concentrated in Yamagata Prefecture, and not all of our group's facilities can be immediately replaced by alternative facilities. Accordingly, if a disaster or accident occurs, damage to manufacturing equipment and other assets, suspension of production lines, compensation to business partners and nearby residents, and other factors may affect our group's business, operating results and financial condition.」
Active pharmaceutical ingredient warehouses and quality testing are conducted at 2 locations, in Kanagawa and Osaka, while drug product production is concentrated in Yamagata Prefecture.